Ultraviolet Light Slated for Review as Carcinogen

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

RESEARCH TRIANGLE PARK, NC-The National Toxicology Program (NTP) plans to review the three wavelength groups of ultraviolet light-UVA, UVB, and UVC-for possible listing in the federal government’s Tenth Annual Report on Carcinogens. The three wavelengths occur in varying amounts in sunlight and in some forms of artificial light, such as that used in sun lamps and tanning beds.

 RESEARCH TRIANGLE PARK, NC—The National Toxicology Program (NTP) plans to review the three wavelength groups of ultraviolet light—UVA, UVB, and UVC—for possible listing in the federal government’s Tenth Annual Report on Carcinogens. The three wavelengths occur in varying amounts in sunlight and in some forms of artificial light, such as that used in sun lamps and tanning beds.

Multilayered reviews are done to determine if a suspected carcinogen should be designated as a known human carcinogen or as reasonably anticipated to be a human carcinogen. The first review is done by scientists at the National Institute of Environmental Health Sciences and a second by scientists from a number of federal agencies. Finally, a panel of outside experts examines the data in a public hearing.

Among other substances being considered for listing:

The fire retardants 2,2-bis-bromo-methylpropanediol and 2,3-dibromo-1-propanol.

Vinyl bromide, which is used in making flame-retardant synthetic fibers.

Vinyl fluoride, used in producing plastics.

Two classes of dyes—the dimeth-oxybenzidines and dimethylbenzidines—used in textiles, leather, plastics, paper, and rubber.

 Styrene-7,8-oxide, used in preparing fragrances and in some epoxy resins.

 IQ, a compound found in cooked meat and fish.

In addition, beryllium and beryllium compounds, currently on the reasonably anticipated list, will be reviewed for possible upgrading to known human carcinogens.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content